Current challenges in cell and gene therapy: a joint view from the European Committee of the International Society for Cell & Gene Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT)

• DOI: 10.1016/j.jcyt.2024.02.007
• Publication Date: 2024-02-17T10:14:04Z
• Authors: Fermin Sanchez-Guijo; Joaquim Vives; Annalisa Ruggeri; Christian Chabannon; Selim Corbacioglu; Harry Dolstra; Dominique Farge; Nico Gagelmann; Claire Horgan; Jurgen Kuball; Benedicte Neven; Tuula Rintala; Vanderson Rocha; Isabel Sanchez-Or...; John A. Snowden; Jaap Jan Zwaginga; Massimiliano Gnecchi; Anna Sureda
• Keywords: JACIE; education; Transplantation; Cancer Research; Immunology; 610; 600; cell and gene therapy; Cell Biology; registry; reimbursement; ATMP; CAR-T; Europe; ISCT; MSC; Laboratory Medicine - Radboud University Medical Center; Oncology; EMA; Journal Article; Immunology and Allergy; Genetics(clinical); benchmarking; ATMPs; EBMT

Cell and gene therapy poses evolving challenges. The current article summarizes the discussions held by European Regional Committee of the International Society for Cell & Gene Therapy and the European Society for Blood and Marrow Transplantation (EBMT) on the current challenges in this field, focusing on the European setting. This article emphasizes the imperative assessment of real-world cell and gene therapy activity, advocating for expanded registries beyond hematopoietic transplantation and chimeric antigen receptor-T-cell therapy. Accreditation's role in ensuring standardized procedures, as exemplified by JACIE (The Joint Accreditation Committee of ISCT-Europe and EBMT), is crucial for safety. Access to commercial products and reimbursement variations among countries underscore the need for uniform access to advanced therapy medical products (ATMPs). Academic product development and point-of-care manufacturing face barriers to patient access. Hospital Exemption's potential, demonstrated by some initial experiences, may increase patient accessibility in individual situations. Regulatory challenges, including the ongoing European ATMPs legislation review, necessitate standardized criteria for Hospital Exemption and mandatory reporting within registries. Efforts to combat unproven therapies and fraud involve collaboration between scientific societies, regulatory bodies and patient groups. Finally, is important to highlight the vital role of education and workforce development in meeting the escalating demand for specialized professionals in the ATMP field. Collaboration among scientific societies, academic institutions, industry, regulatory bodies and patient groups is crucial for overcoming all these challenges to increase gene and cell therapy activity in Europe.